Billionaire Steve Cohen Owns Shares of This Stock That Has Soared 1,600% in The Past Year
2026-03-10 16:20:00 ET
Investing in clinical-stage biotechs generally offers significant upside potential, along with a healthy, above-average dose of risk. Picking the right ones to put your hard-earned money into while avoiding wealth destroyers can be complicated. It might be worth considering some of the ones that prominent figures on Wall Street are investing in.
Take Steve Cohen, the billionaire founder and CEO of Point72 Asset Management, a hedge fund that has delivered outstanding returns over the long run. Point72 Asset Management owns shares of Abivax (NASDAQ: ABVX) , a France-based clinical-stage biotech, whose shares have skyrocketed by more than 1,600% over the trailing 12 months. Is this a great stock for investors to buy?
Image source: Getty Images.
NASDAQ: ABVX
ABVX Trading
2.74% G/L:
$125.59 Last:
545,893 Volume:
$123.99 Open:
